Amgen Inc. $AMGN Stock: D.A. Davidson & CO. Trims Position

D.A. Davidson & CO. reduced its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 1.2% in the third quarter, according to its most recent filing with the SEC. The fund owned 209,707 shares of the medical research company’s stock after selling 2,579 shares during the period. D.A. Davidson & CO.’s holdings in Amgen were worth $88,394,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of AMGN. BlackRock Inc. grew its position in Amgen by 4.8% in the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after acquiring an additional 2,261,544 shares during the last quarter. State Street Corp lifted its position in shares of Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after purchasing an additional 11,656,755 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Amgen by 12.7% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock worth $1,952,156,000 after purchasing an additional 605,928 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Amgen during the second quarter worth $1,831,903,000. Finally, Amundi boosted its stake in shares of Amgen by 15.2% during the second quarter. Amundi now owns 3,890,189 shares of the medical research company’s stock valued at $1,408,715,000 after purchasing an additional 512,883 shares during the period. 76.50% of the stock is owned by institutional investors.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported positive Phase 3 OASIZ-301 results for dazodalibep in Sjögren’s disease, showing statistically significant and clinically meaningful improvements in systemic disease activity and patient-reported dryness. The company will also present additional data for UPLIZNA, KRYSTEXXA and TAVNEOS, reinforcing the potential of its rare-disease and autoimmune pipeline. Amgen autoimmune disease data announcement
• Positive Sentiment: Goldman Sachs and TD Cowen reiterated Buy ratings, supporting the view that Amgen’s oncology, rare-disease and autoimmune portfolio can sustain growth. Goldman Sachs Buy rating TD Cowen Buy rating
• Positive Sentiment: Amgen declared a quarterly dividend of $2.52 per share, or $10.08 annualized, providing continued income support for shareholders. The payment is scheduled for December 11 to shareholders of record on November 20. Amgen fourth-quarter dividend announcement
• Neutral Sentiment: Amgen will release third-quarter 2026 results after the U.S. market closes on November 3. The company has a four-quarter earnings-beat streak, but investors are focused on whether strong drug sales can offset pricing pressure, biosimilar competition and rising costs. Amgen third-quarter 2026 earnings webcast
• Negative Sentiment: The FDA issued a warning concerning promotional material for Amgen’s cancer drug Vectibix, creating regulatory and compliance risk. FDA warning over Vectibix promotion
• Negative Sentiment: Jefferies raised its price target to $428, which remains below the stock’s recently cited trading level and may signal limited near-term upside despite maintaining broader bullish sentiment. Jefferies Amgen price target

Amgen Stock Up 0.9%

NASDAQ:AMGN opened at $451.83 on Thursday. Amgen Inc. has a fifty-two week low of $288.00 and a fifty-two week high of $454.66. The stock has a market capitalization of $244.27 billion, a P/E ratio of 28.08, a P/E/G ratio of 3.21 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The company’s 50-day simple moving average is $418.95 and its 200-day simple moving average is $373.41.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. Amgen’s revenue was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities analysts anticipate that Amgen Inc. will post 22.96 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s payout ratio is currently 62.65%.

Insider Buying and Selling at Amgen

In other news, SVP Rachna Khosla sold 2,000 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at approximately $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Nancy Grygiel sold 2,970 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 6,222 shares of company stock worth $2,540,926 over the last ninety days. Corporate insiders own 0.85% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. BMO Capital Markets cut their price target on shares of Amgen from $450.00 to $415.00 and set a “market perform” rating on the stock in a report on Monday, October 12th. Weiss Ratings raised shares of Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. Wells Fargo & Company decreased their price objective on shares of Amgen from $435.00 to $430.00 and set an “equal weight” rating for the company in a report on Monday, October 12th. Citigroup boosted their price objective on shares of Amgen from $345.00 to $405.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Finally, TD Cowen boosted their price objective on shares of Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, Amgen presently has an average rating of “Hold” and a consensus target price of $389.71.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.